It’s been a big quarter for biotech stocks. Biogen (NASDAQ:BIIB) had a major breakthrough with the approval of its Alzheimer’s vaccine aducanumab, which is sold under the brand name Aduhelm. It marks the first time an Alzheimer’s therapy has been green-lit over 20 years and targets the pathophysiology of the disease. Though there are differing…